Dynavax Technologies (NASDAQ:DVAX) and Obseva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Dynavax Technologies and Obseva, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dynavax Technologies 0 0 4 0 3.00
Obseva 0 0 7 0 3.00

Dynavax Technologies currently has a consensus target price of $28.25, suggesting a potential upside of 133.66%. Obseva has a consensus target price of $29.86, suggesting a potential upside of 74.20%. Given Dynavax Technologies’ higher possible upside, equities research analysts clearly believe Dynavax Technologies is more favorable than Obseva.

Profitability

This table compares Dynavax Technologies and Obseva’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dynavax Technologies -8,570.06% -72.31% -50.92%
Obseva N/A -59.29% -53.39%

Volatility & Risk

Dynavax Technologies has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Obseva has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.

Valuation and Earnings

This table compares Dynavax Technologies and Obseva’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dynavax Technologies $330,000.00 2,294.17 -$95.15 million ($1.73) -6.99
Obseva N/A N/A -$66.92 million ($2.25) -7.62

Obseva has lower revenue, but higher earnings than Dynavax Technologies. Obseva is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

82.1% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 68.3% of Obseva shares are owned by institutional investors. 3.5% of Dynavax Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Dynavax Technologies beats Obseva on 7 of the 12 factors compared between the two stocks.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Obseva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.